Dongwha conducts phase 2 study of novel antibacterial quinolone

Published: 2008-10-06 06:38:00

Updated: 2008-10-06 06:38:00

Dongwha Pharm says it has conducted a local phase 2 study of the oral formulation of DW-224a, a fluoroquinolone antibiotic at seven university hospitals between October 1, 2008 and October 31, 2009.

DW-224a is a newly broad-spectrum fluoroquinolone with potent activity against respiratory trac...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK